Smoking and risk of adult-onset atopic dermatitis in US women - 11/01/21
Doi : 10.1016/j.jaad.2020.07.077
Deanna E. Morra, MPH a, b, Eunyoung Cho, ScD c, d, e, Tricia Li, MD, MS c, e, Carlos A. Camargo, MD, DrPH e, f, g, Abrar A. Qureshi, MD, MPH c, d, e, h, Aaron M. Drucker, MD, ScM b, c, i, ⁎ 
a Faculty of Medicine, University of Ottawa, Ottawa, Canada
b Women's College Research Institute and Department of Medicine, Women's College Hospital, Toronto, Canada
c Department of Dermatology, Warren Alpert Medical School of Brown University, Providence, Rhode Island
d Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island
e Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
f Department of Emergency Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Masschusetts
g Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Masschusetts
h Department of Dermatology, Rhode Island Hospital, Providence, Rhode Island
i Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada
∗Correspondence to: Aaron M. Drucker, MD, ScM, Women's College Hospital, 76 Grenville St, Toronto, ON M5S 1B2, CanadaWomen's College Hospital76 Grenville StTorontoONM5S 1B2Canada
| Funding sources: Supported by a National Institutes of Health grant for the Nurses' Health Study II (UM1 CA176726). |
|
| Disclosure: In the last 3 years, Dr Drucker has served as an investigator and has received research funding from Sanofi and Regeneron; has been a consultant for Sanofi, RTI Health Solutions, Eczema Society of Canada, and Canadian Agency for Drugs and Technology in Health; and has received honoraria from Prime Inc, Spire Learning, CME Outfitters, Eczema Society of Canada, and the Canadian Dermatology Association, and his institution has received educational grants from Sanofi. Author Morra, and Drs Cho, Li, Camargo, and Qureshi have no conflicts of interest to declare. |
|
| IRB approval status: Approved by the Institutional Review Board of the Brigham and Women’s Hospital. The completion and return of self-administered questionnaires was considered to imply informed consent. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 84 - N° 2
P. 561-563 - février 2021 Retour au numéro
Article précédent
- A single-center, retrospective record review of malignancy prevalence in patients with dermatomyositis with anti-transcription intermediary factor 1? antibodies via line immunoassay versus immunoprecipitation
- Skylar Westerdahl, Christopher M. Hull, Jennie T. Clarke, Christopher B. Hansen, Jamie L.W. Rhoads
- COVID-19 outbreak and autoimmune bullous diseases: A systematic review of published cases
- Michael Kasperkiewicz
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?